Pacira Pharma in $45.5M follow-on to commercialise approved pain product
This article was originally published in Scrip
Executive Summary
The specialty pharma company Pacira Pharmaceuticals has priced a new secondary public offering of seven million shares at $6.50, to raise $45.5 million.